HUTCHMED Secures $110 Million Licensing Deal with GSK for Promising Solid Tumour Drug, ETPharma
Shanghai: GSK subsidiary GlaxoSmithKline Intellectual Property (No. 4) Ltd will pay a unit of HUTCHMED (China) $110 million…
Hutchmed Partners with GSK to Develop First-in-Class Cancer Drug in Licensing Deal Worth Up to $1.295 Billion — BigGo Finance
Hutchmed (00013.HK; HCM.US) announced on September 3 that its subsidiary, Hutchison Whampoa Pharmaceutical (Shanghai), has entered into an…
GSK Bets Nearly $1.3 Billion on Hutchmed’s ATTC Platform as Chinese Innovative Drugs Enter the “Selling the Platform” Era — BigGo Finance
British pharmaceutical giant GSK and Chinese innovative drugmaker Hutchmed have reached a licensing agreement worth up to $1.295…